T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

Lymphocyte infiltration (LI) is often seen in breast cancer but its importance remains controversial. A positive correlation of human epidermal growth factor receptor 2 (HER2) amplification and LI has been described, which was associated with a more favorable outcome. However, specific lymphocytes m...

Full description

Saved in:

Bibliographic Details
Published in:	Breast cancer research : BCR Vol. 11; no. 2; p. R15
Main Authors:	Rody, Achim, Holtrich, Uwe, Pusztai, Laos, Liedtke, Cornelia, Gaetje, Regine, Ruckhaeberle, Eugen, Solbach, Christine, Hanker, Lars, Ahr, Andre, Metzler, Dirk, Engels, Knut, Karn, Thomas, Kaufmann, Manfred
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 01-01-2009 National Library of Medicine - MEDLINE Abstracts BioMed Central
Subjects:	Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - genetics Breast Neoplasms - immunology Breast Neoplasms - metabolism Care and treatment Female Gene expression Gene Expression Profiling Gene Expression Regulation, Neoplastic Genetic aspects Health aspects Humans Immunoenzyme Techniques Lymphocyte Specific Protein Tyrosine Kinase p56(lck) - genetics Lymphocyte Specific Protein Tyrosine Kinase p56(lck) - metabolism Neoplasm Staging Oligonucleotide Array Sequence Analysis Patient outcomes Prognosis Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism T-Lymphocytes - metabolism United States Germany
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Lymphocyte infiltration (LI) is often seen in breast cancer but its importance remains controversial. A positive correlation of human epidermal growth factor receptor 2 (HER2) amplification and LI has been described, which was associated with a more favorable outcome. However, specific lymphocytes might also promote tumor progression by shifting the cytokine milieu in the tumor. Affymetrix HG-U133A microarray data of 1,781 primary breast cancer samples from 12 datasets were included. The correlation of immune system-related metagenes with different immune cells, clinical parameters, and survival was analyzed. A large cluster of nearly 600 genes with functions in immune cells was consistently obtained in all datasets. Seven robust metagenes from this cluster can act as surrogate markers for the amount of different immune cell types in the breast cancer sample. An IgG metagene as a marker for B cells had no significant prognostic value. In contrast, a strong positive prognostic value for the T-cell surrogate marker (lymphocyte-specific kinase (LCK) metagene) was observed among all estrogen receptor (ER)-negative tumors and those ER-positive tumors with a HER2 overexpression. Moreover ER-negative tumors with high expression of both IgG and LCK metagenes seem to respond better to neoadjuvant chemotherapy. Precise definitions of the specific subtypes of immune cells in the tumor can be accomplished from microarray data. These surrogate markers define subgroups of tumors with different prognosis. Importantly, all known prognostic gene signatures uniformly assign poor prognosis to all ER-negative tumors. In contrast, the LCK metagene actually separates the ER-negative group into better or worse prognosis.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1465-542X 1465-5411 1465-542X
DOI:	10.1186/bcr2234